Ecnoglutide

Overview

Ecnoglutide, also known by the development code XW003, is an investigational long-acting GLP-1 receptor agonist. Unlike the dual and triple agonists in this section, ecnoglutide focuses on a single, well-studied target: the GLP-1 receptor, which plays a central role in appetite regulation and glucose metabolism.

It is being developed for obesity and type 2 diabetes, the two indications most closely associated with GLP-1-based therapies. The long-acting design is intended to support convenient dosing intervals, a practical feature that can matter for adherence in chronic metabolic conditions.

Ecnoglutide has been notably advancing through clinical development in China, where it has been a focus of trial activity. As with the other compounds described here, it remains investigational, has not received broad regulatory approval as an established global therapy, and should be understood as a candidate still being evaluated rather than a finished product.

How it works

Ecnoglutide acts on the GLP-1 receptor, mimicking the action of the natural incretin hormone GLP-1. Activation of this receptor is associated with increased insulin release in response to meals, reduced appetite, slowed gastric emptying, and improved feelings of fullness. These combined effects can support both better blood sugar control and reduced food intake.

The molecule is engineered to be long-acting, meaning it is designed to remain active in the body for an extended period. This is typically achieved through structural modifications that slow breakdown and clearance, allowing for less frequent administration compared with short-acting agents.

Because ecnoglutide targets a single, well-characterized pathway, its general mechanism is familiar from the broader GLP-1 class. The specific engineering choices that distinguish it, and how they translate into clinical performance, are what its development program is intended to define.

Research & evidence

Ecnoglutide has been studied in clinical trials for obesity and for type 2 diabetes, with development activity advancing notably in China. These programs aim to evaluate its effects on body weight and on blood glucose control, the core outcomes relevant to GLP-1 therapies.

Because it belongs to a well-established mechanistic class, ecnoglutide's general approach is supported by extensive prior experience with GLP-1 receptor agonists. Even so, each individual molecule must demonstrate its own efficacy and safety, and outcomes can differ based on structure, potency, and dosing characteristics. Confirmatory results from its own trial program are what determine its standing.

This encyclopedia avoids quoting specific efficacy figures, participant numbers, or trial dates, since these are best drawn from primary sources and change as studies report. The balanced summary is that ecnoglutide is a long-acting GLP-1 agonist progressing through clinical development, building on a familiar mechanism while awaiting full confirmation of its individual profile.

Safety & legal status

Ecnoglutide's safety profile is still being established through its clinical program. As a GLP-1 receptor agonist, it would be expected to share the general tolerability considerations of that class, where gastrointestinal effects such as nausea, vomiting, and diarrhea are commonly reported, particularly early in treatment. Only its own completed trials can confirm its specific safety characteristics.

Ecnoglutide is investigational and has not received broad regulatory approval as an established global medicine. Where development is most advanced, its status is governed by the relevant national regulators, and it is not a consumer supplement. Any product sold as ecnoglutide outside of legitimate, approved channels should be treated as unregulated and potentially unsafe.

This encyclopedia does not provide dosing information. People interested in GLP-1-based treatments or relevant clinical trials should consult qualified healthcare professionals and rely on approved, properly regulated products rather than seeking investigational compounds independently.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Guo W, Xu Z, Zou H, et al. Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023. Peer-reviewed study
2. Ji L, Gao L, Xue H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025. Peer-reviewed study
3. He Y, Mi N, Cheng Z, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2025. Peer-reviewed study
4. Scheen AJ. Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?. Lancet Diabetes Endocrinol. 2025. Peer-reviewed study
5. Zhu D, Wang W, Tong G, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024. Peer-reviewed study
6. Zhu D, Wang W, Tong G, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun. 2026. Peer-reviewed study